The French glioblastoma biobank (FGB): a national clinicobiological database

Abstract

Background Glioblastomas (GB) are the most common and lethal primary brain tumors. Significant progress has been made toward identifying potential risk factors for GB and diagnostic and prognostic biomarkers. However, the current standard of care for newly diagnosed GB, the Stupp protocol, has remained unchanged for over a decade. Large-scale translational programs based on a large clinicobiological database are required to improve our understanding of GB biology, potentially facilitating the development of personalized and specifically targeted therapies. With this goal in mind, a well-annotated clinicobiological database housing data and samples from GB patients has been set up in France: the French GB biobank (FGB). Methods The biobank contains data and samples from adult GB patients from 24 centers in France providing written informed consent. Clinical and biomaterial data are stored in anonymized certified electronic case report forms. Biological samples (including frozen and formalin-fixed paraffin-embedded tumor tissues, blood samples, and hair) are conserved in certified biological resource centers or tumor tissue banks at each participating center. Results Clinical data and biological materials have been collected for 1087 GB patients. A complete set of samples (tumor, blood and hair) is available for 66%, and at least one frozen tumor sample is available for 88% of the GB patients. Conclusions This large biobank is unique in Europe and can support the large-scale translational projects required to improve GB care. Additional biological materials, such as peritumoral brain zone and fecal samples, will be collected in the future, to respond to research needs.

The von Willebrand Factor stamps Plasmatic Extracellular Vesicles from Glioblastoma Patients

“…Two biocollections were established and registered with plasmatic samples at different time course of glioblastoma progression. For the French Glioblastoma Biobank (#1476342v2, CHU Angers, France), liquid biopsies from glioblastoma patients were sampled at the time of diagnosis (23). For the Integrated Center for Oncology cohort (DC-2015-2457, ICO, Saint Herblain, France), 10 patients with glioblastoma were sequentially sampled at critical points of the Stupp et al protocol (i.e., after resective surgery and upon radio-chemotherapy), during the follow-up and at relapse (24).…”

Precision Neurosurgery: A Path Forward

“…This highlights the urgent need for a sensitive blood biological signature. The use of large biobanks has allowed for multi omics studies to propose biomarkers, defined as a clinical, radiological and biological signatures, that allow the definition of sub-groups of glioblastomas [43,44]. This refers to liquid biopsies whose aim is to propose a diagnosis through a simple blood sample.…”

The Assistance Publique Hôpitaux de Marseille’s Biobank

“…The release date depends on each cohort. Some biological resources under embargo may be available upon request; even for the national collection (eg: Base Clinico Biologique (BCB) Gliomes [10], BCB FREGAT [11], BCB Melbase [12]…).…”